HR-1843 : Still Just a Bill

---

This bill requires the Food and Drug Administration (FDA) to inform generic drug applicants, upon request or during review, whether the drug is qualitatively and quantitatively the same as the listed brand-name drug (and if not, the reasons why). The FDA must also update or publish guidance on how it makes such determinations.

---

An error occured and we cannot provide a prediction at this time. Either Congress API has not provided a text file or subject list for this bill, or the bill text is too large to make a prediction.